KEI comments in FDA-2017-N-3615

On November 17, 2017, KEI provided comments in KEI-FDA-2017-N-3615 These were the topics discussed: Transparency Clinical trial costs Data from the Orphan Drug program Costs of trials for government funded research Asset acquisition costs. Licensing Access to Knowhow, data and materials… Continue Reading

Uncategorized

SCCR 35 Day 1 at WIPO Standing Committee on Copyright and Related Rights: will the “YouTube treaty” progress?

Day 1 at WIPO STANDING COMMITTEE ON COPYRIGHT AND RELATED RIGHTS Since 1998, the WIPO Standing Committee on Copyright and Related Rights (SCCR),has engaged in negotiations to create new norms for the protection of broadcasters, cablecasters and now –again– webcasters… Continue Reading

KEI Comment on GOP proposal to eliminate the Orphan Drug Tax Credit

Statement by James Love, KEI Director, on GOP proposal to eliminate the Orphan Drug Tax Credit.

The GOP proposal to eliminate the Orphan Drug Tax Credit may create a new opportunity to reform the incentives for rare diseases, even if the tax bill fails or the tax credit survives. The GOP tax bill shows there is weaker support for the existing regime than many thought.

Continue Reading

WIPO publishes scoping study scoping study on the impact of the digital environment on copyright legislation

On Thursday, 26 October 2017, the World Intellectual Property Organization (WIPO) published a scoping study (SCCR/35/4) on the impact of the digital environment on copyright legislation adopted between 2006 and 2016; the author of this study is Guilda Rostama, Ph.D. The mandate for this study emanates from a proposal of the Group of Latin American and Caribbean States (GRULAC) first tabled at the 31st session of WIPO’s Standing Committee on Copyright and Related Rights (SCCR) in December 2015. At SCCR33 in November 2016, WIPO Member States agreed to the following:

Continue Reading